Who are Paritaprevir/ritonavir/ombitasvir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Grazaoprevir/Elbasavir/RBV, ABT-450/r/ABT-267.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paritaprevir-ritonavir-ombitasvir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Paritaprevir/ritonavir/ombitasvir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paritaprevir/ritonavir/ombitasvir (Paritaprevir/ritonavir/ombitasvir) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis C virus protease inhibitor and NS5A inhibitor combination. Area: Virology/Hepatology.

phase 3 Hepatitis C virus protease inhibitor and NS5A inhibitor combination HCV NS3/4A protease; HCV NS5A protein Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Paritaprevir/ritonavir/ombitasvir (Paritaprevir/ritonavir/ombitasvir) — AbbVie. Paritaprevir inhibits hepatitis C virus NS3/4A protease, while ritonavir boosts its levels, and ombitasvir inhibits the NS5A protein, together blocking viral replication.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paritaprevir/ritonavir/ombitasvir TARGET	Paritaprevir/ritonavir/ombitasvir	AbbVie	phase 3	Hepatitis C virus protease inhibitor and NS5A inhibitor combination	HCV NS3/4A protease; HCV NS5A protein
Grazaoprevir/Elbasavir/RBV	Grazaoprevir/Elbasavir/RBV	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog	HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase
ABT-450/r/ABT-267	ABT-450/r/ABT-267	AbbVie	phase 3	Hepatitis C virus protease inhibitor and NS5A inhibitor combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis C virus protease inhibitor and NS5A inhibitor combination class)

AbbVie · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paritaprevir/ritonavir/ombitasvir — Competitive Intelligence Brief. https://druglandscape.com/ci/paritaprevir-ritonavir-ombitasvir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab